ESSA Pharma 2021 Investor Presentation

ESSA Pharma is a clinical-stage biotech focused on developing first-in-class N-terminal domain (NTD) inhibitors of the androgen receptor for prostate and hormone-driven cancers. The company's lead candidate EPI-7386 began Phase 1 studies in 2Q2020 with initial focus on castration-resistant prostate cancer, and has raised $150M to support development.